Posted by Michael Wonder on 18 Oct 2023
Health Canada grants market authorisation for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children with cystic fibrosis ages 2 to 5 years with at least one F508del mutation
17 October 2023 - Approximately 330 children with cystic fibrosis ages 2-5 years are now eligible for a medicine that treats the underlying cause of their disease.
Vertex Pharmaceuticals today announced that Health Canada has granted market authorisation for the expanded use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis ages 2 to 5 years who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.
